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Abstract: MicroRNAs (miRNAs or miRs) have a critical role in regulating stem cells (SCs) during
development and altered expression can cause developmental defects and/or disease. Indeed,
aberrant miRNA expression leads to wide-spread transcriptional dysregulation which has been
linked to many cancers. Mounting evidence also indicates a role for miRNAs in the development
of the cancer SC (CSC) phenotype. Our goal herein is to provide a review of: (i) current research
on miRNAs and their targets in colorectal cancer (CRC), and (ii) miRNAs that are differentially
expressed in colon CSCs. MicroRNAs can work in clusters or alone when targeting different SC genes
to influence CSC phenotype. Accordingly, we discuss the specific miRNA cluster classifications and
isomiRs that are predicted to target the ALDH1, CD166, BMI1, LRIG1, and LGR5 SC genes. miR-23b
and miR-92A are of particular interest because our previously reported studies on miRNA expression
in isolated normal versus malignant human colonic SCs showed that miR-23b and miR-92a are
regulators of the LGR5 and LRIG1 SC genes, respectively. We also identify additional miRNAs whose
expression inversely correlated with mRNA levels of their target genes and associated with CRC
patient survival. Altogether, our deliberation on miRNAs, their clusters, and isomiRs in regulation
of SC genes could provide insight into how dysregulation of miRNAs leads to the emergence of
different CSC populations and SC overpopulation in CRC.
Keywords: microRNAs (miRNAs); colorectal cancer (CRC); cancer stem cell genes (CSCs); biomarker(s);
miRNA-17-92a cluster; miRNA-23b-27b-24 cluster; tumor heterogeneity
1. Introduction
Our goal herein is to review current research findings on miRNAs in colorectal cancer
(CRC), and to provide an update on miRNAs that target stem cell (SC) genes in CRC. We
will first provide a brief discussion of the discovery of miRNAs and review of the canonical
and noncanonical miRNA biogenesis pathways. Then, we will identify how dysregulation
of miRNA biogenesis and/or function contributes to cancer. We then discuss and identify
miRNAs and miRNA clusters that target SC genes or the genes involved in regulating SC
properties. Finally, we provide bioinformatics information on miRNAs that are predicted
to target SC genes in CRC, including their miRNA cluster classification and their isomiRs.
The overall focus of this paper is to understand how dysregulation of miRNAs leads to
emergence of cancer SC (CSC) populations and SC overpopulation in CRC.
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2. Discovery of miRNAs
MicroRNAs are the class of short noncoding RNAs, approximately 18–25 nucleotides
in length, which were identified based on their ability to regulate post-transcriptional gene
expression. They are highly conserved across animal species, and essential for normal
animal development and cellular processes such as proliferation, differentiation, viability
and apoptosis [1,2]. Since their discovery, the role of miRNAs in pathogenesis including
cancer, neurological disease, heart disease, autoimmune disease, viral disease, and bone
disease has been well documented [3–8].
The first two miRNAs discovered were heterochronic genes essential for the timing of
developmental events in Caenorhabditis elegans (C. elegans). Lin-4 was the first miRNA to
be identified by the Ambros and Ruvkun research teams in 1993 [9,10]. They found that
lin-4 had an essential role in the growth and differentiation of C. elegans hypodermic stem
cells. Lin-4 was later found to suppress gene expression of lin-28 and lin-14 by binding to
the complementary regions of their 3′ UTRs [11,12]. Although these findings were quite
exciting, this phenomenon seemed restricted to nematode development as there were
no homologs found in vertebrates until a few years later with the discovery of a second
miRNA, let-7 [13,14]. While lin-4 is essential for the transition of larvae from the first to
second stages, let-7 was found to be critical for the timing of later events from larval to the
adult stage. However, unlike Lin-4, Let-7 is highly conserved across animal species [13,14].
Overall, the significance and role of miRNAs in development and adult homeostasis have
revolutionized the field of molecular biology and our understanding of pathogenesis of
cancer and other diseases [12].
3. miRNA Biogenesis
It is important to understand miRNA biogenesis in order to elucidate how miRNA
dysregulation causes cancer and promotes its progression. The biogenesis of miRNAs may
involve a dominant canonical pathway or one of several noncanonical pathways [15].
3.1. Canonical Pathway
In the canonical pathway (Figure 1), biogenesis begins when primary transcript
miRNA (pri-miRNA) is transcribed and then cleaved into precursor-miRNA (pre-miRNA)
by a “microprocessor” complex consisting of the ribonuclease III (RNase III) enzyme Drosha
and RNA binding protein DGCR8 [16–19]. The pre-miRNAs are then exported from the
nucleus into the cytoplasm via the Ran-GTP/Exportin-5 complex [15]. Ran is a GTPase
of the Ras protein superfamily. Exportin-5, like other karyopherin nucleocytoplasmic
transporters, requires the aid of Ran-GTP to export contents from the nucleus into the
cytoplasm [20,21]. Once inside the cytoplasm, pre-miRNA is processed into an miRNA
duplex with the removal of its terminal loop and unwound by the RNase III enzyme
Dicer [15,22]. At this point, single-stranded mature miRNA joins with the RNA-inducing
silencing complex (RISC) to target the mRNA of interest. The RISC complex consists mainly
of Dicer, TRBP, and Argonaute2 (Ago2) [23]. Ago2 is the catalytic center of the RISC and is
required for strand selection and coordination of target gene silencing events [24]. Finally,
the miRNA-induced silencing complex (miRISC) controls gene silencing by cleaving and
degrading target mRNA, or by causing translational repression.
3.2. Noncanonical Pathways
There are several noncanonical pathways of miRNA biogenesis. These alternate
pathways bypass some of the components normally involved in the canonical pathway.
For example, noncanonical miRNA biogenesis may be categorized into Drosha/DGCR8-
independent or Dicer-independent pathways [16]. One example of the Drosha/DCGR8-
independent pathway involves mirtrons which are pre-miRNAs formed by the splicing
of introns and debranching enzymes in the nucleus. They are exported from the nucleus
by Exportin-5 and further processed by Dicer and the RISC in the cytoplasm. An example
of a Dicer-independent pathway involves the short hairpin RNA (shRNA) processing
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by Drosha in the nucleus. It is then exported for further processing by Ago2 and the
miRISC in the cytoplasm. Recall, Argonaute proteins are a group of proteins that aid in the
incorporation of miRNAs with the RISC complex in both the canonical and noncanonical
pathways [24,25]. These and other noncanonical pathways are further reviewed in [26].
























Figure 1. Canonical miRNA biogenesis pathway. RNA polymerase II transcribes DNA of interest into pri-miRNA containing
~80 nucl otides (nts). The Drosha/DGCR8 microprocessing complex cleaves pri-miRNA into pre-miRNA which contains
~65 nts. The Ran-GTP/Exportin-5 complex binds to pre-miRNA and expor s it from the nucleus into the cytoplasm. Dicer
aids in un inding and transfor ing pre- i into an i duplex. The i duplex is then further processed by
RISC and Ago2 into mature miRNA containing ~22 nts. Then the miRNA-induced silencing complex miRISC either causes
cleavage and degradation or translational repression of its target mRNA.
4. Dysregulation of miRNAs in Cancer
A role for miRNAs in the development and progression of cancer is well established.
In normal tissue, as regulators of gene expression, miRNAs aid in maintaining proper
cellular homeostasis. However, in most cancers, miRNAs have been found to be greatly
dysregulated [16,27–31]. Alteration in the level of miRNA expression can occur at all stages
of tumorigenesis including tumor initiation, progression and metastasis. Specific tumor
types can also show a distinct miRNA signature which distinguishes them from their
normal tissue of origin and from other cancer types. Some of the consequences of altered
miRNA expression that contribute to cancer progression are dysregulated cell growth [31],
cell motility in tumorigenesis [32], and/or alteration in hormonal stress response [33].
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Dysregulation of miRNAs has been shown to lead to tissue changes that are cardinal
features of malignant transformation, including sustained proliferation, evasion of tumor
suppression, avoidance of apoptosis, activation of invasion and metastasis, and induction
of angiogenesis and drug resistance [27,28]. By causing these changes, miRNAs can act like
either oncogenes or tumor suppressors [29]. Although abnormal expression of miRNAs in
cancer cells is a widely accepted phenomenon, the causes of this dysregulation are still not
yet fully understood. Below, we discuss how deregulation of miRNAs is associated with:
(i) defects in miRNA biogenesis with a focus on how Let-7 affects protein synthesis, and (ii)
epigenetic alterations with a focus on aberrant DNA methylation.
4.1. Defective Biogenesis
Defects in miRNA biogenesis itself is one of the mechanistic ways in which miRNAs
can lead to cancer progression as both the canonical and noncanonical pathways involve
several intermediate factors that are tightly regulated. For example, Dicer protein expres-
sion was inhibited in multiple cells lines as a result of reactive oxygen species, phorbol
esters, and Ras oncogene stress responses [33]. Low levels of dicer expression and func-
tionality are linked to the development and poor survival prognosis of patients with the
following cancer types: breast, lung, liver, bladder, and colorectal [34]. Overexpression of
Ago1 and Ago2, Dicer, and Drosha were observed in ovarian cancer [35]. Exportin-5 was
found to play an oncogenic role in CRC, where high expression levels associated with the
worst clinicopathology and poor CRC patient survival [36].
4.2. Discovery of the LET-7 Family
The identification of the first two miRNAs in C. elegans, lin-4 and let-7, led to the
discovery of miRNAs in other species and how they are evolutionarily conserved. Indeed,
LET-7 was discovered as the first known human miRNA. Studies on LET-7 and LET-7 family
members provided the first insight into how miRNAs affect molecular processes in the
human body and how its dysregulation causes disease. In fact, LET-7 is widely known as a
tumor suppressor and when under-expressed is associated with poor prognosis in at least 20
different cancers [37]. As tumor suppressors, the Let-7 family (12 members), downregulates
oncogenes such as c-MYC, k-RAS, Cyclin D1 and others [38]. In mammals, the biogenesis
of Let-7 is inhibited by the highly conserved RNA binding proteins- Lin28A and Lin28B.
In turn, Let-7 binds to the 3′ UTR of Lin28 mRNAs to inhibit their expression. In this way,
the LIN28/Let-7 pathway operates in a double negative feedback loop and overexpression
of LIN28A or LIN28B is correlated with cancer progression [39] in several different cancer
types including liver [40], breast [41], and lung [42]. Balzeau et al. reported on the clinical
relevance of LIN28A/LIN28B in a table that lists the aforementioned cancers and others,
which highlights the impact of the LIN28/Let-7 pathway in cancer development [43].
4.3. DNA Methylation and miRNA Expression
Epigenetic changes due to DNA methylation are known to lead to miRNA dysfunction
and contribute to cancer development [15,44]. Indeed, the process of DNA methylation has
been shown to occur in unique miRNAs in various cancer types such as oral cancer [45],
breast cancer [46], and glioblastoma [47]. DNA methylation affects miRNA expression by
silencing or promoting gene transcription. An emerging hallmark of cancer is CpG island
hypermethylation of miRNAs that function as tumor suppressors [44]. An example of this
was seen in a study evaluating methylation of genes known to be dysregulated in CRC,
including adenomatous polyposis coli (APC), where aberrant hypermethylation was observed
in the promoter sequence of APC [48].
Since miRNAs were implicated in the promotion and suppression of metastasis in
breast cancer [49–51], Lujambio et al. set out to determine if a unique miRNA hypermethy-
lation profile characteristic of metastasis could be identified [44]. The following miRNAs:
miR-9-1, miR-9-2, miR-9-3, miR-34b, miR-34c, miR-148a were found to undergo silencing
from hypermethylation which induced metastasis. Although each of the aforementioned
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miRNAs had varying degrees of hypermethylation, in CRC, miR-9-3 had the highest preva-
lence at 84% followed by miR-148a (39%), miR-34b/c (35%), mir-9-1 (32%), and mir-9-2 (16%)
(Table S3 in [44]). In contrast, the frequency of miRNA hypermethylation was roughly
equal among lung cancers, ranging from 52–56%. In melanoma, miR-9-2 hypermethyla-
tion was the most prevalent (64%). Breast as well as head and neck tumors were also
profiled, but the most notable was that seen for miR-9-2 in malignant colon tissues. In
terms of normal tissue, the miRNAs were not significantly methylated which indicates that
hypermethylation of CpG islands is largely correlated with cancer [44].
Alternatively, there are also cases of DNA hypomethylation that affect the control of
miRNA expression in cancer as well. For example, hypomethylation of CpG islands just
upstream of miR-196b led to its overexpression and enhanced cell invasion and migration
in oral squamous cell carcinoma [45]. The silencing of miR-196b implicated it as having
a role in cell invasion and metastasis [45]. Interestingly, there is some level of duality
in terms of miRNA function, wherein a particular miRNA can be tumor promoting in
one cancer and tumor suppressing in another. For example, miR-196b hypomethylation
causes its overexpression and promotes progression of oral squamous cell cancer, and its
hypermethylation causes tumor suppressor activities in lung carcinoma [52].
The modification of DNA that occurs in methylation is mediated by DNA methyltrans-
ferases (DNMTs) [53]. One example of how these enzymes facilitate cancer progression is
by transcriptional repression [54]. In glioblastoma, overexpression of DNMTs is associated
with hypermethylation of tumor suppressor genes [55], and the miR-296-5p tumor sup-
pressive ability (downregulation of stemness genes) was reversed by DNMT-dependent
hypermethylation [47]. On the other hand, DNMT3b was found to directly repress stem-
ness genes in breast cancer [46]. The authors found that miR-221 acts as a suppressor and
downregulates DNMT3b expression by binding to its 3′ untranslated region (3′ UTR). In
doing so, the downregulation of DNMT3b by miR-221 aids in breast tumorigenesis by
alleviating its repression of stemness [46]. Thus, the functional variability in DNA methyla-
tion and the role of its targeted miRNAs is evident in the dysregulated gene expression in
different cancer types.
5. miRNA Clusters and Their Role in Tumor Development
Since their discovery, genome-wide studies identified several hundred evolutionarily
conserved miRNAs essential for diverse biological processes through their regulation of
gene expression. A recent study estimated there are possibly 2300 mature miRNAs that
exists in the human genome [56]; an update to the miRBase database report accounted
for 2656 around the same time [57]. miRNAs are typically encoded in between genes
(intergenic), but some are encoded within introns (intragenic) of pre-miRNAs or noncoding
RNAs [58]. In this way, it is quite reasonable to understand how miRNAs may be grouped
or clustered together. This phenomenon is also evolutionarily conserved, and in humans,
approximately 40% of miRNA genes are clustered [58]. Large clusters may be transcribed
as a single polycistronic transcript encoding for multiple miRNAs with similar expression
patterns and either similar or different functions. Polycistronic miRNAs have also been
shown to regulate each other and when disrupted, can result in developmental defects [59].
Genomic redundancy, where homologous polycistrons are found on multiple chro-
mosomes, implicates a common function. An example is shown where miR-99a/100, let7,
and miR125b converge to block the TGFβ pathway and upregulate Wnt signaling in the
disruption of hematopoietic stem cell homeostasis in acute megakaryoblastic leukemia
(AMKL) [60]. However, opposing functions of individual members of the aforementioned
polycistron, miR-99a/100 [61] and LET-7 [62] were also identified. Therefore, understanding
how clusters (and their individual miRNAs) function is important as they may prove use-
ful in therapeutic targeting [63]. Altogether, given the functional variability of individual
miRNAs and clusters, it is of no surprise that dysregulation can result in different disease
types. In this section, we will identify and review current literature on two clusters and
their individual miRNA members implicated in colon and other cancers.
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5.1. miR-17-92 Cluster
MiR-17-92 is one of the most characterized clusters, known as an oncogene, but respon-
sible for a variety of disease pathologies. This cluster regulates biological processes such as
cell proliferation, apoptosis, metabolism, metastasis, and tumorigenesis. Its overexpression
is well-established in a variety of tumor cells and cancer types including colon [64] and
lung [65,66]. The miR-17-92 cluster is polycistronic, located on human chromosome 13,
and encodes for 7 individual mature miRNAs miR-17-3p, miR-17-5p, miR-18a, miR-19a,
miR-19b-1, miR-20a and miR-92a-1 [4]. Various roles of the miR-17-92 cluster in neurological,
heart disease, and bone development are reviewed in [4]. In tumorigenesis, the cluster
as a whole and/or by its individual members targets either of three major pathways that
regulate cell proliferation and/or apoptosis: JAK/STAT, PI3K/AKT/mTOR, and PTEN [4].
The functional variety of target genes and subsequent pathways they regulate may explain
the cell- and context-dependent role of miR-17-92.
Elevated levels of miR-17-92 were associated with tumorigenesis [67–69] and poor
survival rates in CRC [70]. A direct link between oncogenic miR-17-92 and tumor suppres-
sor APC was discovered where β-catenin upregulated expression of miR-17-92 in APC
mutant cells, and wt-APC caused degradation of β-catenin and reduced miR-17-92 [71].
miR-17-92 downregulated multiple components of TGFβ signaling to evade cell cycle
arrest and/or apoptosis in neuroblastoma [72], and upregulation of miR-17-92 by c-Myc
caused downregulation of TGFβ signaling pathway components to stimulate angiogenesis
and tumor growth [73]. Conversely, an anti-angiogenic role was identified in CRC where
miR-17-92 downregulated angiogenic inducing genes: TGFBR2, HIF1α, and VEGFA [74],
and a tumor suppressive role was identified in prostate cancer [75].
Individual miRNAs within a cluster can have differing functions from the group
and/or from each other. For example, miR-18a was correlated with APC mutations and is
highly expressed in colon tumors [76]. miR-19a and miR-19b are essential for oncogenic ac-
tivity of the entire miR-17-92 cluster by reducing PTEN expression and its tumor suppressor
activity [77]. miR-20 activates cyclin-dependent kinase inhibitor 1A/p21 (CDKN1A/p21),
which negatively regulates TGFβ, and thus prevents its antiproliferative effect in CRC [4].
In addition, miR-17-5p and miR-20 reduced expression of TGFβ-receptor type II and miR-18
limited expression of Smad4 [73].
5.2. miR-92a Family
While miR-92a is part of the mir-17-92 cluster, miR-92a is also a member of a conserved
miRNA family: miR-92a-1, miR-92a-2, miR-363 and miR-25. The miR-92a family arose from
three different paralog clusters miR-17-92, miR-106a-363, and miR-106b-25 that occurred
during evolution. Studies on miR-92a reveal it plays a key role in regulating organ de-
velopment and tumorigenesis, and is overexpressed in several tumors including: colon,
prostate, lung, pancreatic, stomach, pancreas, and others [78]. A recent study discovered
that overexpression of miR-92a caused increased proliferation of glioma cells by targeting
the KLF4/AKT/mTOR pathway [79]. Several mechanisms involving the downregulation
of tumor suppressor and apoptosis genes and upregulation of cell proliferation have been
implicated in the tumorigenic role of miR-92a in CRC [80–84]. Furthermore, high expression
levels of miR-92a correlated with tumor metastasis and poor prognosis [85–87] and it is
demonstrated to be a novel diagnostic biomarker [88] in CRC. It is important to note, an
opposing role for miR-92a was observed in breast cancer, where downregulation of miR-92a
was associated with aggressive features and increased macrophage infiltration [89].
5.3. miR-23b-27b-24 Cluster
The miR-23b-27b-24 cluster is not as well-characterized as the miR-17-92 cluster and its
role in cancer has been controversial and understudied. Most studies focus instead on the
function of its individual miRs: miR-23a/b, miR-27a/b, and miR-24-1/2. Nevertheless, two
paralogs exist in humans, the miR-23b-27b-24-1 cluster, which is encoded within an intron
on the C9orf3 gene located on chromosome 9, and miR-23a-27a-24-2 located on chromosome
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19. The two paralogs are predicted to have the same gene targets, but so far only ~15% of
the predicted shared targets that have been validated as discussed in [90].
In a recent study, the miR-23b/27b/24 cluster has been found to aid in the process of cell
migration in a subset of cells with high migration capacity in several CRC cell lines [91].
This study is interesting because it addresses the issue of heterogeneity of tumor cells. In
this way, miR-23b/27b/24 may be considered tumor progressive as cell migration is required
for tumor invasion, metastasis, and epithelial to mesenchymal transition (EMT) of cells.
The authors also examined the individual miRNAs of the cluster and determined that
only miR-23b and miR-27b were effective in regulating cell migration by direct inhibition of
FOXP2 (miR-24 did not). FOXP2 was recently implicated as a suppressor of metastasis and
identified as a possible prognostic marker in breast cancer [92]. Downregulation of FOXP2
by the miR-23b-27b-24-1 cluster and two of its individual members warrants the further
investigation of clusters as this approach may have greater therapeutic value than for
individual miRNAs. In line with this finding, the cluster, but not its individual members,
conferred resistance to oxaliplatin by modulating EMT in CRC [93].
The miR clusters may display oncogenic or tumor suppressive roles depending on
their context. The tumor suppressive ability of miR-23b/27b/24-1 was demonstrated in
prostate cancer (PCa). Expression of miR-23b-27b-24-1 was reduced in clinical PCa tissue
specimens, and gain of function studies resulted in reduced cell proliferation, migration,
and invasion in two PCa cell lines [94]. In non-small cell lung cancer (NSCLC), miR-23b-
27b-24-1 is downregulated by altered expression of platelet-derived growth factor (PDGF).
Abnormal expression of PDGF receptors is a clinical prognostic marker for the worst cases
of NSCLC. Induced expression of miR-23b-27b-24-1 increased drug sensitivity and reduced
invasiveness of NSCLC cells by silencing gene members of the oncogenic NF-κB and KRAS
pathways [95], also identifying a tumor suppressive role for this cluster.
Individual members of miR-23b-27b-24-1 also display varying roles in different cancer
types. In breast cancer, miR-23b and miR-27b was shown to promote oncogenesis [96]. miR-
23b and miR-27b are highly expressed in vascularized tissues and epithelial cells. miR-23b
and miR-27b also promote angiogenesis by downregulating anti-angiogenic proteins, and
their inhibition repressed angiogenesis [97]. However, miR-27b is downregulated in colon
cancer by c-SRC and KRAS, suggesting a tumor suppressive role. This role was confirmed
by finding that miR-23b downregulates ARFGEF1 and paxillin expression to prevent tumor
growth and invasion of colon cancer [98]. Individually, miR-23b has a role in a variety of
cellular processes including cell differentiation, immunity, and cancer progression. This
single miRNA is pleiotropic, exhibiting gene regulation of a variety of cellular processes in
the human body [99]. Thus, its dysregulation can lead to a variety of disease pathologies,
including tumor progression or suppression. miR-23b expression is downregulated in CRC,
and several targets: TGFβR2, uPA, MAP3K1, PAK2, FZD7 [100] and PDE7A [101] have
been identified, implicating a tumor suppressive role. A genome-wide study revealed
the ability of miR-23b to subdue tumor metastasis [99]. However, the role of miR-23b in
metastasis was more recently found to be context-dependent, as it cooperates with BTBD7
to promote metastasis in CRC [102]. We will discuss how miR-92a and miR-23b contribute
to the development of different populations of stem cells in CRC below, but first we will
discuss cancer stem cell theory.
6. Cancer Stem Cell Theory and the Role of miRNAs
In CRC development, SC overpopulation has been found to be a driver of tumor
initiation and progression by us [103–107] and others [108–110]. Since miRNAs have a
critical role in regulating SCs during development, and altered expression of miRNAs
occurs in various cancers, our focus has been to study whether miRNA dysregulation
is involved in the SC origin of CRC. We conjecture that different CSC populations are
generated by the dysregulation of different miRNAs. We will begin by discussing one of
the first proteins (CD44) identified as a SC marker and how it provided an explanation for
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the role of miRNA dysregulation in carcinogenesis. Then we will explore how miRNAs
might regulate expression of SC genes and lead to CSC populations in CRC.
6.1. CD44
The hyaluronate receptor/P-glycoprotein 1 (CD44) is a transmembrane protein [111],
which has been widely studied as a SC marker for various cancer types. The function
of CD44 involves interactions with different ligands, especially hyaluronidase [112]. In
breast cancer and cervical cancer, CD44 interacts with the beta-catenin and Akt pathways
which promote epithelial to mesenchymal transition often observed in carcinogenesis [113].
Recent studies on human CRC show that CD44, when coupled with LGR5, can efficiently
identify cancer SCs [114]. CD44 has also been looked at with another biomarker called
aldehyde dehydrogenase 1 (ALDH1). Together CD44 and prominin-1/AC133 (CD133)
along with ALDH1 were studied as biomarkers that can track stem cell overpopulation
during CRC formation [111].
CD44 is an example of one of the many biomarkers that can explain how miRNA
dysregulation is correlated with carcinogenesis. Studies on CD44 expression in CRC
showed that modulating Dicer expression led to changes in CSCs and miRNAs [34]. For
example, impairment of DICER1 function led to an upregulation of CD44, Sox9, Sox2,
Nanog, and Lgr5. In cells with impaired Dicer function, a reduction of multiple miRNAs
that target CD44 and the Wnt/beta-catenin pathway mediated the upregulation of CD44
expression. Impaired DICER1 was also linked to the generation of subpopulations of
CRC cells with enhanced SC features and plasticity displayed by the interconversion
between heterogeneous CRC cell subtypes. Tumor heterogeneity and cellular plasticity can
enhance the progression of CRCs as tumor cells acquire an ability to withstand therapy-
induced selection pressure [115]. A consequence of dysregulated DICER1 function and
deregulation of miRNAs that promotes stemness is an enhanced ability to initiate tumors
and metastasis [34].
6.2. Other SC Markers
The role of aberrant miRNA expression in CSCs in cancer has recently been the
subject of several reviews [116–119]. We will provide an update by discussing miRNAs
and the SC genes they are predicted to target in CRC. First, we provide a brief review
of the SC genes (ALDH, CD166, LGR5, LRIG1, BMI1) that are the focus of this paper.
Aldehyde dehydrogenase (ALDH) is a marker discovered by us and others that identifies
SCs in normal and malignant colonic tissues and can track SC overpopulation during
tumor growth [111,120,121]. ALDH1 is the enzyme responsible for metabolizing retinal
into retinoic acid and is known to play an important role in cellular differentiation [122].
ALDH1 has also been found to be a SC marker for many other human cancers such as breast,
lung, and ovary [123,124]. Next, CD166 (ALCAM) was identified and these CD166+ cells
were shown to possess tumor-initiating ability [125]. Then, BMI1, LGR5, and LRIG1 were
identified as SC markers in humans as well as mice [126–128]. The LGR5 transmembrane
protein is expressed in proliferating SCs and observed to be responsible for expansion of
the SC compartment and adenoma formation in mice [109,127]. BMI1, a member of the
polycomb protein family, is a hematopoietic SC marker that is over-expressed in various
tumor types [127,129–131]. LRIG1 is a pan-ERBB negative regulator and promotes SC
quiescence in the epidermis and the intestinal tract [128,132,133]. These markers and
several others have been used to identify and isolate different CSC populations from CRCs
(reviewed in [107,134–137]). However, there is a paucity of data to understand how these
different CSC populations develop and are maintained in CRCs. We explore the possible
role of miRNAs as is presented in this paper.
7. miRNAs Implicated in Development of CRC Stem Cell Populations
Our recent studies have investigated how miRNAs might regulate expression of
SC genes and lead to the development of the different CSC populations [136] and their
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overpopulation in CRC. Indeed, an investigation of the literature shows that many miRNAs
have been reported to target SC genes or genes involved in regulating SC properties
(Table S1). Moreover, using miRNA expression profiling of isolated normal and malignant
human colonic SCs [138,139], we showed that miR-23b and miR-92a are regulators of the
LGR5 and LRIG1 SC genes, respectively. Findings from these two published studies and
from our review of TCGA study results are described further below.
7.1. miRNA23b
Our study designed to analyze miRNA expression in the colonic SC niche using micro-
dissected human colonic crypts identified a set of miRNAs that distinguishes malignant
from normal colonic epithelium [138]. Notably, miR-23b, which was increased in CRC,
was predicted to target the LGR5 SC gene. We also showed that miR-23b regulates CSC
phenotypes globally at the level of proliferation, cell-cycle, self-renewal, EMT, invasion,
and resistance to 5-FU. miR-23b decreased LGR5 expression and increased the number of
ALDH+ CSCs. We confirmed that levels of LGR5 and miR-23b are inversely correlated
(p < 0.05) in ALDH+ CSCs, and that distinct populations of LGR5+ and ALDH+ CSCs
exist. Overall, our study defined a critical function for miR-23b, which, by targeting LGR5,
contributes to overpopulation of ALDH+ CSCs and CRC.
7.2. miRNA92a
We also took an independent approach to identify miRNAs in purified human colonic
SCs [139], which was based on a more extensive screen involving miRNA expression
profiling of ALDH+ SCs isolated from fresh normal colonic epithelium and CRC tissue.
This was done to identify additional miRNAs involved in the SC origin of CRC. We used
Nanostring expression profiling to analyze miRNAs (n = 800) in SCs purified from fresh
normal and malignant colonic tissues. We found: (1) a unique miRNA signature that
differentiated ALDH+ CSCs from ALDH+ normal SCs; (2) expression of four miRNAs
(miR-200c, miR-92a, miR-20a, miR-93) were upregulated in CRC CSCs compared to normal
colonic SCs; (3) miR-92a was upregulated in ALDH+ HT29 CRC CSCs; (4) miR-92a targeted
the 3′UTR of LRIG1; and (5) miR-92a modulated proliferation of HT29 CRC cells. Thus, our
findings indicated that overexpression of miR-92a also contributes to the SC origin of CRC.
8. miRNAs Predicted to Target CRC Stem Cell Genes
A review of miRNAs that target SC genes in normal versus cancerous colonic tissues
was done herein using the two sets of miRNAs (n = 164 total miRNAs) from our previous
published studies on differentially expressed miRNAs in colon CSCs [138,139]. A literature
review was then done to see whether these miRNAs are reported to target SC genes in
normal colon vs. CRC. The miRNAs from these two studies on colonic SCs [138,139] were
cross referenced with miRNAs reported in the TCGA database for: (a) miRNA expression
in normal vs CRC tissue, (b) prediction of target SC genes, (c) whether the expression of a
miRNA inversely correlates with the mRNA levels of the target gene, and (d) correlation of
the expression of miRNAs with CRC patient survival and other clinical parameters. The
results (Table 1) showed that 53 miRNAs are predicted to target the SC genes analyzed in
the study and 39 of them showed differences (p < 0.01; Table S2) in expression between
normal and CRC tissues (see examples in Figure 2). Of the miRNAs, 13 are predicted to
target more than one SC gene. We further classified these miRNAs that are predicted to
target SC genes based on the miRNA clusters that they are part of along with the other
members of the cluster, including the changes in miRNA expression between normal colon
vs. colon cancer (Table S2). The specific miRNA isoform (isomiR) that is predicted to target
the SC genes is also given in Table S2. Figure 2 gives some examples of isomiR expression
in normal colon compared to CRC. Figure 3 shows examples of survival curves for CRC
cases based on expression of these same isomiRs selected by inverse mRNA expression of
target SC genes.
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Table 1. Survey of miRNAs (n = 216) aberrantly expressed in CRCs that target stem cell genes *.
ALCAM ALDH Isoforms BMI1 LGR Isoforms LRIG Isoforms
mir-142-5p mir-182-5p miR-106b mir-142 mir-20a-5p mir-218-2-5p
mir-148a-3p mir-23a-3p miR-107 mir-23b mir-023a-3p mir-92a-1
mir-148b-3p mir-23b-3p miR-153-2 mir-218-2-5p mir-023b-3p mir-93-5p
mir-152-3p mir-27a-3p miR-154-3p let-7a-1-5p mir-106a-5p let-7a-1-5p
mir-9-1-5p mir-27b-3p miR-208b let-7a-2-5p mir-106b-5p let-7a-2-5p
mir-9-2-5p mir-31-5p miR-218-2-5p let-7a-3-5p mir-129-1-p5 let-7a-3-5p
miR-27a let-7b-5p mir-129-2-p5 let-7b-5p
miR-302c let-7c-5p mir-130b-3p let-7c-5p
miR-033b let-7d-5p mir-16-1-5p let-7d-5p
miR-539-3p let-7e-5p mir-16-2-5p let-7e-5p
miR-548j let-7f-1-5p mir-17-5 let-7f-1-5p
miR-548h let-7f-2-5p mir-200c let-7f-2-5p
let-7g let-7g-5p mir-208b let-7g-5p
* Survey of the TCGA database done using MIR-TV tool (http://mirtv.ibms.sinica.edu.tw/). Note: isomiRs refer to the mature miRNA
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Figure 3. Kaplan−Meyer CRC survival curves for miRNA cases selected by their SC target gene versus all other cases,
X-axis = years.
9. Discussion
Our previous and ongoing studies indicate that miRNAs target SC genes in normal
colonic epithelium, and when dysregulated, these miRNAs play a role in the SC origin
of colon carcinomas. Indeed, we previously reported that miR-23b and miR-92a are reg-
ulators of the LGR5 and LRIG1 SC genes, respectively. Our review of data reported in
the TCGA study indicates that other miRNAs also target SC genes and many miRNAs
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show differences in expression between normal and CRC tissues. Several of these miRNAs
are members of the same miRNA cluster and other members within the cluster are also
predicted to target SC genes. Moreover, the expression of a number of the miRNAs in-
versely correlates with the mRNA levels of the target gene, and expression of the miRNAs
correlates with CRC patient survival and other clinical parameters. Several points bear
further discussion.
9.1. What Is the Role of Isomers in the Development of Different CSC Populations?
We also considered isomiRs based on differences in their SC target prediction because
recent findings show that variations in miRNA sequences are known to display differences
in expression in various types of tissues and cancers [140,141]. Indeed, it has been found
that isomiR expression profiles distinguish different breast cancer subtypes [142]. Our
findings herein show that different isomiRs from the same reference miRNA can differ
in their ability to target a given SC gene. We also found that some 3p and 5p isomiRs
differ with regard to being upregulated or downregulated in CRC versus normal colon. In
addition, the association of a miRNA with CRC patient survival often correlated with just
one or the other of the isomiRs from the same reference miRNA. These findings indicate
that each isomiR has a distinct impact on the transcriptome of colon CSCs.
9.2. How Might miRNA Expression Lead to the Development of Different CSC Populations
in CRC?
Our findings show that specific miRNAs are selectively expressed in different human
colon CSC populations and some of these miRNAs target known SC genes. For example, we
found that levels of LGR5 and miR-23b are inversely correlated in ALDH+ colon CSCs, and
that distinct subpopulations of LGR5+ and ALDH+ CSCs exist [138]. Moreover, we found
that transfection of human CRC cells with miR-23b precursor increased the proportion of
ALDH+ cells and transfection with the miR-23b anti-miRNA had the opposite effect. We
also found that miR-92a, which targets the 3′UTR of LRIG1, is upregulated in ALDH+ colon
CSCs and miR-92a modulates CRC cell proliferation [139]. Further review of data from the
TCGA database was done herein to identify miRNAs that target SC genes in normal versus
cancerous colonic tissues using a set of miRNAs from our previous studies on miRNAs
in CRC. These results reveal that many miRNAs predicted to target SC genes inversely
correlate with levels of SC gene expression and CRC patient survival. Taken together, these
results indicate that miRNAs that target SC genes in a given CSC population suppress
expression of specific SC genes expressed in other CSC populations (and vice versa). Our
results indicate that miRNAs, when dysregulated, play a major role in the development of
different populations of CSCs and SC overpopulation in CRC.
10. Conclusions
In this manuscript, we have reviewed miRNA expression in colon CSCs in order to
identify mechanisms that can explain the development of different CSC populations in
CRC. Our previous miRNA expression profiling of isolated normal and malignant human
colonic SCs showed that miR-23b and miR-92a are regulators of the LGR5 and LRIG1 SC
marker genes, respectively. Our further online investigation of these miRNAs indicates
that many miRNAs predicted to target SC genes regulate SC gene expression and correlate
with CRC patient survival. Thus, we conjecture that miRNAs contribute to regulation of
SC genes and genes involved in regulation of SCs and, when dysregulated, contribute to
the emergence of different CSC populations and SC origin of CRC.
Continued research on mechanisms that explain how miRNAs regulate normal colon
SCs and how dysregulation of miRNAs in CSCs drives CRC growth should provide insight
into how new SC-targeted therapies might be designed for CRC. For example, miRNA
studies could provide insight into how different CSC subpopulations arise in CRC and
advance our understanding of how tumor heterogeneity occurs. It could also provide
clues as to how to eliminate CSCs and improve the efficacy of anticancer therapies. For
example, novel, effective therapeutics could be designed to: (1) directly target miRNAs
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identified as vital to specific CSC populations; and/or (2) modulate CSC composition
in order to therapeutically sensitize tumors. Indeed, an emerging field is focusing on
combining miRNAs with other drugs to modulate dysregulated miRNAs and sensitize
cancers to conventional or immunotherapy agents [143–147]. Thus, the significance of this
deliberation is that discovering how to modulate the function of miRNAs may provide
a mechanism to reverse changes in miRNA expression patterns and to therapeutically
target CSCs. Overall, discovery of miRNAs that regulate CSCs offers great potential for
improving cancer research and clinical oncology practice paradigms.
Supplementary Materials: The following are available online at https://www.mdpi.com/1422-006
7/22/3/1424/s1. Table S1: miRNAs predicted to target SC genes or genes involved in regulating SC
functions. Table S2: Classification of miRNAs based on the miRNA clusters and isomiR.
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